Here are some of my main learning points from this podcast, with Guy Elitzur, CEO of EcoPhage, a company which is enlisting viruses to fight bacteria that cause diseases in crops:
- Bacteriophages are bacteria-eating viruses. These viruses were discovered in the nineteenth century, but have only really been studied more intensively in the past couple of decades.
- Guy’s company has licensed the same technology, from Israel’s Weizmann Institute, as licensed by the Nasdaq-listed BiomX, a pharmacological company looking to tackle bacterial diseases in humans. In that sense, this makes an interesting example where the agriculture sector is applying existing human remedies to crop diseases, in a push to reduce environmental impact.
- Bacterial diseases in crops are across the board, including in row crops, and fruit and vegetables. Guy’s company is starting with control of bacterial diseases in tomatoes.
- Regulation looms large behind the drivers for this company. To date, bacterial diseases in crops are mostly treated with antibiotics or copper-based chemical products. Regarding antibiotics, bacterial resistance is leading regulators to reduce or ban their use. Meanwhile, copper is toxic. So, farmers are under pressure to find something new.
- Regulatory pressure to find safer solutions also confer practical commercial benefits. Chemicals manufacturers face a real burden to prove that their products are safe, which biocontrol developers can avoid through certain waivers. Guy says that his company can develop a new product in 12 to 18 months, versus 10 to 15 years for a chemical solution, partly for this reason, and partly because they are starting with a virus which already destroys bacteria, and so is halfway there, instead of designing from scratch a chemical to do this.
- The company’s process starts with sourcing virus bacteriophages from the natural environment, and then screening these for potency. The company will combine good candidates in cocktails, to make them collectively tougher to crack, in terms of bacterial resistance.
- Guy says that trials suggest his product, integrated into current farming practice, confers tens of percentage point benefits, in yield and other core attributes. He says that will also be 10-15% more expensive, a cost offset by the superior performance. He expects to start commercialising the product for tomatoes at the beginning of 2025.
- He expects the competitive landscape to become more intense, from just a handful of bacteriophage companies in the agriculture space today.
Become a supporter of this podcast:
https://www.spreaker.com/podcast/new-food-finance-podcast--5682894/support.
